Normalizing the exceptional: incorporating the "abortion pill" into mainstream medicine

Area of Science:

• Medical Sociology
• Pharmaceutical Policy
• Reproductive Health

Background:

• Mifepristone (RU-486) received FDA approval in the US in September 2000 after a prolonged struggle.
• The drug's integration into mainstream healthcare is complicated by the cultural and medical context of abortion in America.
• Efforts to introduce mifepristone are characterized by attempts to 'normalize the exceptional'.

Purpose of the Study:

• To discuss the integration process of mifepristone into mainstream US healthcare.
• To analyze the sociological implications of introducing mifepristone.
• To identify and examine the unique challenges in the diffusion of mifepristone compared to typical medications.

Main Methods:

• Historical overview of mifepristone's FDA approval process.
• Analysis of standard medication integration processes in the US.
• Contrast of mifepristone's integration with typical drug diffusion, highlighting external and internal obstacles.

Main Results:

• Integration faces significant external obstacles: conflict between FDA-approved protocols and evidence-based alternatives, physician dispensing requirements, ultrasonography ambiguity, and legal/reimbursement issues.
• Internal challenges include inter-specialty conflicts, physician-clinician turf issues, concerns about 'cowboy medicine', and patient compliance.
• The pharmaceutical company's role in mifepristone diffusion differs from traditional models.

Conclusions:

• The introduction of mifepristone highlights the complexities of integrating a highly scrutinized medication into routine medical practice.
• Sociological implications stem from the ongoing effort to normalize a drug associated with abortion within the US medical and cultural landscape.
• Addressing multifaceted challenges is crucial for successful and equitable patient access to mifepristone.